Expiry
-
{
- All
- News
- Videos
- Photos
- Web Stories
-
GLP-1 Drugs In India: How To Spot Fakes Before It's Too Late
Counterfeit GLP-1 drugs like semaglutide are rising in India amid growing demand and multiple cheaper versions entering the market.
-
Affordable Weight Loss Drugs In India: How Cheap GLP-1s Will Affect Obesity Treatment
Replacing traditional weight management methods with GLP-1 medications can be effective for some, but it's essential to approach this transition with caution.
-
Tirzepatide And Semaglutide: Experts Explain New Diabetes, Obesity Drug Options
With semaglutide's patent expiry in India, cheaper generics may expand access to obesity and diabetes care. Experts weigh benefits, risks, and how tirzepatide compares as a next-generation dual-action therapy.
-
Ozempic Copycats Arrive: From Rs 11,000 To Rs 3,000, How Patent Expiry Is Reshaping Diabetes Treatment
With patent protection ending, Indian companies have moved quickly to introduce lower-cost versions with monthly therapy expected at around Rs 3,000 to Rs 4,000 for initial doses
-
Weight Loss Injection For ₹900? Three Pharma Firms Launch Affordable Semaglutide, Check Prices
Indian pharmaceutical companies have launched affordable versions of semaglutide injections following a patent expiry, significantly lowering costs for diabetes and weight management treatment and improving access for millions of patients.
-
Indian Pharma Giants Launch Low-Cost Generic Semaglutide Injections For Diabetes, Weight Management
New Delhi, March 21 (IANS) Three Indian pharmaceutical companies have launched generic versions of semaglutide injections, after the drug’s patent expired, offering lower‑cost options for patients managing Type 2 diabetes and obesity.
-
How Semaglutide Works: Understanding Appetite, Hormones And Weight Loss In Simple Terms
Semaglutide belongs to a class of medicines that act on GLP-1 receptors, which play a major role in appetite, digestion and metabolism.
-
Semaglutide Patent Expires: Will Diabetes, Weight-Loss Treatment Become More Accessible For Patients?
Patent expiry does not signal a change in the medicine itself. Rather, it marks the beginning of wider competition, which typically leads to price reductions and improved availability.
-
Higher-Dose Wegovy Gets US Nod, Trials Show Over 20% Average Weight Loss, Says Drugmaker
Novo Nordisk said it plans to launch the new formulation, (semaglutide 7.2 mg), in the United States in April 2026.
-
Affordable Semaglutide Is Coming: Should You Be Worried About Drug Safety, Health Risks And Side Effects?
India's healthcare landscape will change as semaglutide patents expire in 2026, allowing over 50 generic versions to enter the market and improve access for diabetes and obesity treatment.
-
GLP-1 Drugs In India: How To Spot Fakes Before It's Too Late
Counterfeit GLP-1 drugs like semaglutide are rising in India amid growing demand and multiple cheaper versions entering the market.
-
Affordable Weight Loss Drugs In India: How Cheap GLP-1s Will Affect Obesity Treatment
Replacing traditional weight management methods with GLP-1 medications can be effective for some, but it's essential to approach this transition with caution.
-
Tirzepatide And Semaglutide: Experts Explain New Diabetes, Obesity Drug Options
With semaglutide's patent expiry in India, cheaper generics may expand access to obesity and diabetes care. Experts weigh benefits, risks, and how tirzepatide compares as a next-generation dual-action therapy.
-
Ozempic Copycats Arrive: From Rs 11,000 To Rs 3,000, How Patent Expiry Is Reshaping Diabetes Treatment
With patent protection ending, Indian companies have moved quickly to introduce lower-cost versions with monthly therapy expected at around Rs 3,000 to Rs 4,000 for initial doses
-
Weight Loss Injection For ₹900? Three Pharma Firms Launch Affordable Semaglutide, Check Prices
Indian pharmaceutical companies have launched affordable versions of semaglutide injections following a patent expiry, significantly lowering costs for diabetes and weight management treatment and improving access for millions of patients.
-
Indian Pharma Giants Launch Low-Cost Generic Semaglutide Injections For Diabetes, Weight Management
New Delhi, March 21 (IANS) Three Indian pharmaceutical companies have launched generic versions of semaglutide injections, after the drug’s patent expired, offering lower‑cost options for patients managing Type 2 diabetes and obesity.
-
How Semaglutide Works: Understanding Appetite, Hormones And Weight Loss In Simple Terms
Semaglutide belongs to a class of medicines that act on GLP-1 receptors, which play a major role in appetite, digestion and metabolism.
-
Semaglutide Patent Expires: Will Diabetes, Weight-Loss Treatment Become More Accessible For Patients?
Patent expiry does not signal a change in the medicine itself. Rather, it marks the beginning of wider competition, which typically leads to price reductions and improved availability.
-
Higher-Dose Wegovy Gets US Nod, Trials Show Over 20% Average Weight Loss, Says Drugmaker
Novo Nordisk said it plans to launch the new formulation, (semaglutide 7.2 mg), in the United States in April 2026.
-
Affordable Semaglutide Is Coming: Should You Be Worried About Drug Safety, Health Risks And Side Effects?
India's healthcare landscape will change as semaglutide patents expire in 2026, allowing over 50 generic versions to enter the market and improve access for diabetes and obesity treatment.
